Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program

Authors: Lee, Hae-Young; Oh, Byung-Hee

Source: Expert Review of Cardiovascular Therapy, Volume 7, Number 3, March 2009 , pp. 251-257(7)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Aliskiren is the first in a new class of orally effective direct renin inhibitors. Initial results of clinical efficacy studies have demonstrated at least equivalent or superior blood pressure-lowering efficacy when compared with existing drugs, and a favorable side-effect profile either as monotherapy or as a component of combination therapy. This report aims to introduce and provide a critical appraisal of the initial results of the ASPIRE HIGHER program, evaluating the potential cardio-renal protective effects of aliskiren.

Keywords: albuminuria; aliskiren; heart failure; hypertension

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14779072.7.3.251

Affiliations: 1: Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul, 110-744 Korea

Publication date: 2009-03-01

More about this publication?

Expert Review of Cardiovascular Therapy provides expert commentary on the clinical applications of the new medicines, therapeutic agents and diagnostics in cardiovascular disease. Coverage inculdes drug therapy, heart disease, vascular disorders, hypertension, cholesterol in cardiovascular disease, heart disease, stroke, heart failure and cardiovascular surgery.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites